Acurx Ready To Expand Pipeline With Anthrax Treatment

Readers familiar with my prior research on Acurx Pharmaceuticals (NASDAQ: ACXP ) know that I have a generally negative view on the antibiotics subsector of drug development due to many new antibiotics being used as a Analyst's Disclosure: I/we have a beneficial long position in the shares of ACXP either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no busine ...